AstraZeneca’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks Consensus Estimate. Core earnings of $2.17 per share rose 10% year over ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 billion investment to expand there, as President Donald Trump pressures ...

British pharmaceutical giant AstraZeneca on Tuesday said net profit rose 27 percent in the second quarter, boosted by record growth in its key US market.

AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the United States. Revenue climbed 12 percent to ...

TACO or tariffs? An August 1 deadline looms after the European Union became the latest of the top US trading partners to ...

The United States and the European Union agreed on a framework trade deal to end months of uncertainty for industries and ...

European stocks rallied Tuesday, lifted by a slew of corporate earnings and as investors further assessed the impact of the EU-US trade agreement.US President Donald Trump's agreement with the ...

In European equities on Tuesday, the CAC 40 in Paris gained 0.6%, while the DAX 40 in Frankfurt was up 1.4%. They had ended down 0.4% and 1.0% on Monday.

Astrazeneca has revealed a jump in revenue from cancer drugs amid rumours its boos is eyeing a listing across the pond. Total ...

AstraZeneca PLC (NASDAQ: AZN) ranks among the stocks to benefit from an onshoring boom. AstraZeneca PLC (NASDAQ:AZN) ...

AstraZeneca beat second-quarter earnings expectations on Tuesday, helped by strong sales of key cancer, heart and kidney ...

The country of origin effect is often observed in expensive or status-related products, such as wine and cars. Vaccines, on ...